By taking cells from patients and growing them in the lab into structures that maintain the characteristics of the patient, pharma has the tools to speed drug discovery and tailor treatments to the individual, suggests Colin Sanctuary.
20 Jul 2016
Lausanne, Switzerland

By taking cells from patients and growing them in the lab into structures that maintain the characteristics of the patient, pharma has the tools to speed drug discovery and tailor treatments to the individual, suggests Colin Sanctuary.

With the ratio of early drug candidates to eventually-approved drugs standing at between 5,000-to- 1 and 10,000-to- 1, the drug development process is enormously costly and a pressing issues for pharma. According to the latest study published by the Tufts Center for the Study of Drug Development (CSDD) in the May 2016 issue of the Journal of Health Economics, the average cost to develop and gain marketing approval for a new drug is estimated at $2.558 billion. In its study, the CSDD notes that higher failure rates for drugs tested in humans are the primary reasons behind rising drug development costs…..

Continue reading…

Back to News and Media